RE:nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

RE:nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

Published:2015-08-06 Issue:9 Volume:107 Page:djv204
ISSN:0027-8874
Container-title:Journal of the National Cancer Institute
language:en
Short-container-title:JNCI.J

Author:

Palani Velu Lavanniya K.,Steele Colin W.,Dickson Euan J.,Carter C. Ross,McKay Colin J.,Horgan Paul G.,McMillan Donald C.,Jamieson Nigel B.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/107/9/djv204/7679407/djv204.pdf

Reference7 articles.

1. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial;Goldstein;J Natl Cancer Inst,2015

2. A Prospective Comparison of the Prognostic Value of Tumor- and Patient-Related Factors in Patients Undergoing Potentially Curative Surgery for Pancreatic Ductal Adenocarcinoma

3. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study

4. Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges

5. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma;Denley;J Gastrointest Surg,2013

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of P-MAPA Immunotherapy Associated with Gemcitabine on Chemically-Induced Pancreatic Cancer in Animal Model: New Therapeutic Perspectives;Biointerface Research in Applied Chemistry;2021-11-25

2. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer;Journal of Experimental & Clinical Cancer Research;2018-10-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3